Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating maintenance therapy with Sacituzumab Tirumotecan (MK-2870) versus standard of care in platinum-sensitive recurrent ovarian cancer is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Sacituzumab Tirumotecan (MK-2870) (sacituzumab tirumotecan)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Status: RECRUITING